GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cryofocus Medtech (Shanghai) Co 6922.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.99

-2.45%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥95.3m

FY2020FY2025

Net income

−CN¥38.2m

FY2020FY2025

Free cash flow

−CN¥6.6m

FY2020FY2025

Shareholders' equity

CN¥49.7m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
RevenueCN¥95.3mCN¥45.5mCN¥34.8mCN¥23.1mCN¥19.1mCN¥7.7m
Gross profitCN¥64.0mCN¥32.7mCN¥26.4mCN¥16.5mCN¥13.2mCN¥3.9m
Research and developmentCN¥30.4mCN¥62.4mCN¥64.7mCN¥50.9mCN¥76.4mCN¥36.0m
Operating income−CN¥42.5m−CN¥93.6m−CN¥89.3m−CN¥100.1m−CN¥107.2m−CN¥135.4m
Net income−CN¥38.2m−CN¥88.7m−CN¥82.9m−CN¥95.4m−CN¥86.6m−CN¥116.5m
Diluted earnings per share-0.16-0.37-0.35-0.39-0.35-0.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsCN¥137.5mCN¥126.9mCN¥180.9mCN¥266.8mCN¥197.0mCN¥63.2m
Cash and short-term investmentsCN¥35.0mCN¥38.6mCN¥87.9mCN¥192.5mCN¥134.2mCN¥28.1m
Total liabilitiesCN¥87.7mCN¥64.1mCN¥43.7mCN¥63.5mCN¥51.9mCN¥20.5m
DebtCN¥16.8mCN¥32.1mCN¥6.6mCN¥6.7mCN¥5.4mCN¥107,961
Shareholders' equityCN¥49.7mCN¥62.8mCN¥137.3mCN¥203.3mCN¥145.1mCN¥42.7m
Shares outstanding239m239m239m245m245m245m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−CN¥5.8m−CN¥70.5m−CN¥81.5m−CN¥96.9m−CN¥53.1m−CN¥29.1m
Capital spending−CN¥770,000−CN¥1.6m−CN¥12.8m−CN¥7.0m−CN¥10.6m−CN¥1.3m
Free cash flow−CN¥6.6m−CN¥72.1m−CN¥94.4m−CN¥103.9m−CN¥63.7m−CN¥30.4m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
RevenueCN¥44.2mCN¥51.1mCN¥29.0mCN¥16.6mCN¥18.7mCN¥16.1mCN¥14.3mCN¥8.8m
Gross profitCN¥29.7mCN¥34.3mCN¥19.7mCN¥13.0mCN¥14.0mCN¥12.4mCN¥10.4mCN¥6.0m
Operating income−CN¥16.3m−CN¥26.2m−CN¥46.4m−CN¥47.2m−CN¥49.3m−CN¥40.0m−CN¥62.2m−CN¥37.9m
Net income−CN¥14.4m−CN¥23.8m−CN¥44.4m−CN¥44.3m−CN¥46.0m−CN¥36.9m−CN¥59.1m−CN¥36.3m
Diluted earnings per share-0.06-0.10-0.19-0.19-0.19-0.15-0.24-0.15
Cash from operations—−CN¥6.0m−CN¥70.0m−CN¥42.0m−CN¥81.0m−CN¥49.0m−CN¥82.0m−CN¥33.0m
Capital spending——−CN¥1.0m−CN¥1.0m−CN¥12.0m−CN¥1.0m−CN¥5.0m−CN¥1.0m
Free cash flow——−CN¥71.0m−CN¥43.0m−CN¥93.0m−CN¥50.0m−CN¥87.0m−CN¥34.0m
Total assetsCN¥137.5mCN¥159.8mCN¥126.9mCN¥157.0mCN¥180.9mCN¥218.2m——
Cash and short-term investmentsCN¥35.0mCN¥63.7mCN¥38.6mCN¥59.1mCN¥87.9mCN¥135.2m——
DebtCN¥16.8mCN¥30.8mCN¥32.1mCN¥27.7mCN¥6.6mCN¥6.2m——
Shareholders' equityCN¥49.7mCN¥57.5mCN¥62.8mCN¥100.2mCN¥137.3mCN¥174.6m——

Financial ratios

Data as of 4 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin67.2%71.8%75.8%71.3%69.3%51.2%
Operating margin-44.6%-205.6%-256.6%-433.6%-562.4%-1759.3%
Net margin-40.1%-195.0%-238.1%-413.4%-454.3%-1514.1%
Return on equity-76.7%-141.3%-60.4%-46.9%-59.7%-272.6%
Return on assets-27.8%-69.9%-45.8%-35.8%-44.0%-184.4%
Free cash flow yield-1.2%-17.1%-19.8%———
Revenue growth78.0%30.7%50.8%21.1%147.7%—
Earnings growth-63.4%7.1%-13.1%10.2%-25.7%—
Current ratio1.51x1.64x4.87x5.78x6.69x2.17x
Debt to equity0.26x0.41x0.00x0.00x0.00x0.00x
Equity ratio36.2%49.5%75.9%76.2%73.7%67.6%
Interest coverage-21.77x-94.87x-61.82x-38.16x-46.64x-102.31x
R&D as a share of sales31.9%137.2%185.9%220.8%400.5%467.3%
Buybacks as a share of market value0.0%0.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue59.1%64.2%—
Operating income-24.8%-20.7%—
Net income-26.3%-20.0%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin68.6%70.2%69.5%—
Operating margin-96.7%-163.8%-252.0%—
Net margin-90.1%-153.6%-225.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-37.3-19.1-30.2-25.2
Price to sales15.638.572.1105.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.